The metaboloepigenetic dimension of cancer stem cells: Evaluating the market potential for new metabostemness-targeting oncology drugs

Current Pharmaceutical Design

Volumn 21, Issue 25, 2015, Pages 3644-3653

  Menendez, Javier A ^a,b  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b Metabostem   (Spain)

Author keywords

Cancer stem cells; Drugs; Epigenetics; Metabolism; Metabostemness

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER METABOSTEMNESS; CANCER RESEARCH; CANCER STEM CELL; CANCER THERAPY; CELL KILLING; CELL METABOLISM; CELL PLASTICITY; CELLULAR PARAMETERS; DNA METHYLATION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ENERGY METABOLISM; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; METABOLOEPIGENETIC; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NEOPLASM; ONCOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MODIFICATION; ANIMAL; CELL SELF-RENEWAL; DRUG EFFECTS; ECONOMICS; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SELF RENEWAL; DRUG DISCOVERY; DRUG INDUSTRY; ENERGY METABOLISM; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84940938882     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150710150327     Document Type: Article

References (74)

1. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res 2006; 66(4): 1883-90.
2. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26(17): 2813-20.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10): 755-68.
4. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28(25): 4006-12.
5. Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 2010; 46(7): 1198- 203.
6. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223(2): 147-61.
7. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100(9): 672-9.
8. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci USA 2009; 106(33): 13820- 5.
9. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 2014; 13(7): 497-512.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.
11. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9(4): 265-73.
12. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15(9): 1010-2.
13. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108(19): 7950-5.
14. Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-44.
15. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with nonstem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 2011; 108(4): 1397-402.
16. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci USA 2012; 109(36): 14470-5.
17. Scheel C, Weinberg RA. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22(5-6): 396-403.
18. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21(3): 283-96.
19. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59(1): 168-79.
20. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501(7467): 328-37.
21. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014; 54(5): 716-27.
22. Friedmann-Morvinski D, Verma IM. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 2014; 15(3): 244-53.
23. Varga J, De Oliveira T, Greten FR. The architect who never sleeps: tumor-induced plasticity. FEBS Lett 2014; 588(15): 2422-7.
24. Wang J, Lu F, Ren Q, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011; 71(23): 7238-49.
25. Muñoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012; 6(6): 620-36.
26. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21(4): 473-87.
27. Amente S, Lania L, Majello B. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim Biophys Acta 2013; 1829(10): 981-6.
28. Wu Y, Wang Y, Yang XH, et al. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep 2013; 5(1): 224-36.
29. Yin F, Lan R, Zhang X, et al. LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1- mediated deacetylation of histone H4 at lysine 16. Mol Cell Biol 2014; 34(2): 158-79.
30. Tung PY, Knoepfler PS. Epigenetic mechanisms of tumorigenicity manifesting in stem cells. Oncogene 2015; doi: 10. 1038/onc. 2014. 172.
31. Marjanovic ND, Weinberg RA, Chaffer CL. Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle 2013; 12(17): 2713-4.
32. Norton L. Cancer stem cells, EMT, and seeding: a rose is a rose is a rose? Oncology (Williston Park) 2011; 25(1): 30-32.
33. Donohoe DR, Bultman SJ. Metaboloepigenetics: interrelationships between energy metabolism and epigenetic control of gene expression. J Cell Physiol 2012; 227(9): 3169-77.
34. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16(1): 9-17.
35. Katada S, Imhof A, Sassone-Corsi P. Connecting threads: epigenetics and metabolism. Cell 2012; 148(1-2): 24-28.
36. Martinez-Pastor B, Cosentino C, Mostoslavsky R. A tale of metabolites: the cross-talk between chromatin and energy metabolism. Cancer Discov 2013; 3(5): 497-501.
37. Salehzadeh-Yazdi A, Asgari Y, Saboury AA, Masoudi-Nejad A. Computational analysis of reciprocal association of metabolism and epigenetics in the budding yeast: a genome-scale metabolic model (GSMM) approach. PLoS One 2014; 9(11): e111686.
38. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 2015; 518(7539): 413-6.
39. Teslaa T, Teitell MA. Pluripotent stem cell energy metabolism: an update. EMBO J 2015; 34(2): 138-53.
40. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest 2013; 123(9): 3652-8.
41. Morin A, Letouzé E, Gimenez-Roqueplo AP, Favier J. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. Int J Cancer 2014; 135(10): 2237-48.
42. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3(7): 730-41.
43. Menendez JA, Alarcón T, Joven J. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle 2014; 13(5): 699-709.
44. Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, et al. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 2015; 6(14): 12279-96.
45. Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer 2014; 14(8): 568-73.
46. Menendez JA, Corominas-Faja B, Cuyàs E, Alarcón T. Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience 2014; 1(12): 803-6.
47. Nam H, Campodonico M, Bordbar A, et al. A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks. PLoS Comput Biol 2014; 10: e1003837.
48. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez- Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10(21): 3658-77.
49. Menendez JA, Joven J, Cufí S, et al. The Warburg effect version 2. 0: metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12(8): 1166-79.
50. Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer. Adv Exp Med Biol 2014; 824: 117-40.
51. Menendez JA. Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle 2015: [Epub ahead of print].
52. Menendez JA, Alarcón T. Metabostemness: a new cancer hallmark. Front Oncol 2014; 4: 262.
53. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011; 10(22): 3871-85.
54. Chaterjee M, van Golen KL. Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res 2011; 2011: 362938.
55. Rausch V, Liu L, Apel A, et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012; 227(3): 325-35.
56. Gong C, Bauvy C, Tonelli G, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stemlike/ progenitor cells. Oncogene 2013; 32(18): 2261-72, 2272e. 1- 11.
57. Guan JL, Simon AK, Prescott M, et al. Autophagy in stem cells. Autophagy 2013; 9(6): 830-49.
58. Choi DS, Blanco E, Kim YS, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells 2014; 32(9): 2309-23.
59. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med 2010; 10(7): 674-91.
60. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin- Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor- initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126(2): 355-64.
61. Vazquez-Martin A, López-Bonetc E, Cufí S, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011; 14(4-5): 212-23.
62. Vazquez-Martin A, Vellon L, Quirós PM, et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 2012; 11(5): 974-89.
63. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) 2012; 4(6): 393-401.
64. Vazquez-Martin A, Cufi S, Lopez-Bonet E, et al. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep 2012; 2: 964.
65. Vazquez-Martin A, Corominas-Faja B, Cufi S, et al. The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle 2013; 12(2): 207-18.
66. Cuyàs E, Corominas-Faja B, Menendez JA. The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget 2014; 5(12): 3970-82.
67. Cufi S, Corominas-Faja B, Vazquez-Martin A, et al. Metformininduced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012; 3(4): 395-8.
68. Corominas-Faja B, Cuyàs E, Gumuzio J, et al. Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget 2014; 5(18): 8306-16.
69. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138(4): 645-59.
70. DeLaBarre B, Hurov J, Cianchetta G, Murray S, Dang L. Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem Biol 2014; 21(9): 1143-61.
71. Wang J, Lu F, Ren Q, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011; 71(23): 7238-49.
72. Mould DP, McGonagle AE, Wiseman DH, Williams EL, Jordan AM. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date. Med Res Rev 201; 35(3): 586-618.
73. [No authors listed] IDH1 inhibitor shows promising early results. Cancer Discov 2015; 5(1): 4.
74. de Botton S. O11. 3Targeting isocitrate dehydrogenase (IDH)1 and IDH2 mutations Clinical results in advanced hematologic malignancies. Ann Oncol 2015; 26 (Suppl 2): ii15.